Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.

Metformin use in obese mothers improves cardiovascular profile in offspring

17 Aug 2020

Prenatal exposure to metformin is associated with lower central haemodynamic and cardiac diastolic indices among children of obese mothers, a study has found.

A total of 151 children aged 3.9±1.0 years were included, of whom 77 had been exposed to metformin prenatally. No significant difference was seen in peripheral blood pressure, arterial stiffness, and body composition, except for gluteal and tricep circumference, which were lower in those exposed to metformin (p<0.05)

Children of obese mothers who were exposed to metformin, compared to placebo, had lower central haemodynamics (mean adjusted decrease, –0.707 mm Hg for aortic systolic blood pressure, –1.65 mm Hg for aortic pulse pressure, and –2.68 percent for augmentation index; pall<0.05) and lower left ventricular diastolic function (adjusted difference in left atrial area, –0.525 cm2; in isovolumic relaxation time, –0.324 msec; and in pulmonary venous systolic wave, 2.97 cm/s; pall<0.05).

No significant between-group differences were observed in metabolic profile.

“These results suggest that the administration of metformin in obese pregnant women potentially may have a beneficial cardiovascular effect for their offspring,” the investigators said.

This study measured body composition, peripheral blood pressure, and arterial pulse wave velocity in children from the Metformin in Obese Pregnant Women trial. An oscillometric device was used to estimate central haemodynamics (central blood pressure and augmentation index). Left ventricular cardiac function and structure were evaluated by echocardiography.

“Maternal obesity increases the risk for pregnancy complications and adverse neonatal outcome and has been associated with long-lasting adverse effects in the offspring, including increased body fat mass, insulin resistance, and increased risk for premature cardiovascular disease,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.